세계의 조제 약국 시장 : 제품별, 조제 유형별, 치료 용도별, 무균성별, 최종 사용자별 예측(-2030년)

The global compounding pharmacy market is projected to reach USD 19.41 billion by 2030 from an estimated USD 14.72 billion in 2025, at a CAGR of 5.7% from 2025 to 2030. The market's growth has mainly been driven by the increasing trend toward personalized doses.

However, capacity constraints in API, excipient supply, and CCI/testing are expected to limit the market.

The oral drugs held the highest share in the compounding pharmacy market by product type.

The compounding pharmacy market is segmented by product type into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a key position in the global market, driven by the increasing need for personalized therapies tailored to individual patient requirements. This segment includes a wide variety of formulations such as capsules, tablets, lozenges, solutions, and suspensions, which are extensively used in hormone replacement therapy, pediatric and geriatric care, pain management, gastrointestinal treatments, and chronic disease management. Compounded oral medications enable pharmacists to customize dosage strengths, flavors, excipients, and release profiles, thereby improving patient compliance-especially among those who have difficulty swallowing standard tablets or who need precise dosing. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and endocrine disorders further fuels this segment's growth by creating demand for personalized oral treatments that maximize efficacy and reduce side effects. Technological innovations, including sustained-release systems, taste-masking techniques, and bioavailability-enhancing carriers, improve therapeutic performance and patient experience. Adherence to FDA regulations and USP standards ensures safety, sterility, and quality, building confidence among healthcare providers and patients. Along with the growing emphasis on personalized medicine and increased availability through hospitals, specialty clinics, and retail pharmacies, oral drugs continue to be a major driver of revenue growth. The segment's focus on convenience, customization, and effective therapy highlights its vital role in the overall development of the global compounding pharmacy market.

The pain management segment reported the highest share of the therapeutic application segment in 2024

The pain management segment holds the largest share in the pharmaceutical market by therapeutic application, driven by the global prevalence of acute and chronic pain conditions across musculoskeletal, neuropathic, and post-surgical patient groups. Increasing cases of arthritis, back pain, cancer-related pain, and migraines have boosted demand for effective pain relief therapies, including NSAIDs, opioids, topical analgesics, and combination treatments. The rising use of personalized pain management options, such as sustained-release formulations and targeted delivery systems, improves effectiveness while reducing systemic side effects, further increasing patient adherence and market growth. Technological advances, like transdermal patches and localized injectable therapies, have broadened treatment choices and made long-term pain management more convenient for patients. Favorable insurance coverage, greater awareness of pain as a key health issue, and the expanding elderly population support consistent growth in this segment. Leading pharmaceutical firms are enhancing their portfolios through research into new analgesics, biologics, and non-opioid alternatives, positioning themselves to capture larger market shares. As the need for safe, effective, and patient-focused pain management solutions continues to grow, this therapeutic segment is expected to stay dominant, reflecting sustained revenue increases and ongoing innovation in both developed and emerging markets.

North America accounted for the largest market share in the global Compounding pharmacy market from 2025 to 2030.

North America remains the leading region in the global compounding pharmacy market, mainly due to the United States. The region's dominance is linked to its strong healthcare infrastructure, strict regulatory standards, and a large presence of both 503A and 503B compounding pharmacies. These pharmacies are essential in providing personalized medications, especially where commercially available drugs are insufficient. The US market offers a wide variety of compounded products, including oral, topical, and sterile preparations, to meet different therapeutic needs. Recent trends show a rising demand for specialized compounded medications, particularly in pain management, hormone replacement therapy, and pediatric care. Regulatory agencies like the FDA continue to monitor and ensure the safety and effectiveness of compounded drugs, building trust within the healthcare system. This combination of factors highlights North America's key role in advancing and improving access to compounding pharmacy services.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side-70% and Demand Side-30%
• By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
• By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Key players in the Compounding pharmacy market include Baxter (US), Empower Pharmacy (US), B. Braun (Germany), Fagron (Netherlands), QuVa Pharma (US), SCA Pharma (US), Nephron Pharmaceuticals (US), Leiters Health (US), Pharmaxo (UK), Icon Group (Australia), Roseway Labs (UK), ITH Pharma (UK), Pencol Compounding Pharmacy (Canada), Formula 8 (South Africa), and Aurora Compounding Pharmacy (Canada)

Research Coverage:

This research report categorizes the compounding pharmacy market by product (oral, topical, parenteral), compounding type (ingredient alteration, dosage alteration), therapeutic application (pain management, HRT), sterility (sterile), and end user (pediatric, adult). The scope of the report includes detailed information about the main factors affecting the growth of the Compounding pharmacy market, such as drivers, restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments like new approvals, launches, collaborations, acquisitions, and other updates related to the Compounding pharmacy market.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing them with the closest estimates of revenue figures for the entire Compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report will enable stakeholders to grasp the market's key indicators and offer information on the main market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (Resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances.), opportunities (Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts and Radiopharmaceutical compounding standardization), and challenges (Capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation.) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the Compounding pharmacy market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
    • 2.2.1.2 Revenue share analysis
    • 2.2.1.3 MnM repository analysis
    • 2.2.1.4 Primary interviews
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
• 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
  • 3.2.1 STARTUPS AND INNOVATIVE COMPANIES
  • 3.2.2 ESTABLISHED MARKET LEADERS

4 PREMIUM INSIGHTS

• 4.1 COMPOUNDING PHARMACY MARKET OVERVIEW
• 4.2 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT AND COUNTRY (2025)
• 4.3 COMPOUNDING PHARMACY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 COMPOUNDING PHARMACY MARKET: EMERGING VS. DEVELOPED MARKETS
• 4.5 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
• 4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
• 4.8 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Persistent drug shortages in North America and Europe
    • 5.2.1.2 Enforcement of USP standards
    • 5.2.1.3 Push for ready-to-administer (RTA) and standardized doses
    • 5.2.1.4 Continued demand-supply gap for GLP-1 drugs
    • 5.2.1.5 Trend towards personalization of doses
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Resolution of GLP-1 shortages and reduced reliance on compounded alternatives
    • 5.2.2.2 Stricter FDA oversight and intensified enforcement of unsanitary conditions violations
    • 5.2.2.3 Limitations on bulk drug substances
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts
    • 5.2.3.2 Radiopharmaceutical compounding standardization
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing
    • 5.2.4.2 Limited quality-system maturity and gaps in stability/BUD evidence generation
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT OF NEW ENTRANTS
  • 5.3.2 THREAT OF SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF SUPPLIERS
  • 5.3.4 BARGAINING POWER OF BUYERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.4.2 KEY BUYING CRITERIA
• 5.5 MACROECONOMICS INDICATORS
  • 5.5.1 HEALTHCARE EXPENDITURE TRENDS
  • 5.5.2 GLOBAL CANCER BURDEN
  • 5.5.3 IMPACT OF PHARMA R&D
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 ROLE IN ECOSYSTEM
• 5.8 PRICING ANALYSIS
  • 5.8.1 INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024
  • 5.8.2 INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024
• 5.9 KEY CONFERENCES & EVENTS, 2025-2026
• 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.11 INVESTMENT & FUNDING SCENARIO
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Automated compounding devices
    • 5.12.1.2 Sterile compounding equipment
  • 5.12.2 COMPLEMENTARY TECHNOLOGIES
    • 5.12.2.1 Quality control & testing systems
    • 5.12.2.2 Pharmacy information management software (PIMS)
  • 5.12.3 ADJACENT TECHNOLOGIES
    • 5.12.3.1 3D printing of pharmaceuticals
    • 5.12.3.2 Personalized medicine platforms
• 5.13 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET
• 5.14 REGULATORY ANALYSIS
  • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
  • 5.14.2 REGULATORY FRAMEWORK
• 5.15 IMPACT OF 2025 US TARIFF ON COMPOUNDING PHARMACY MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 KEY TARIFF RATES
  • 5.15.3 PRICE IMPACT ANALYSIS
  • 5.15.4 IMPACT ON COUNTRY/REGION
    • 5.15.4.1 US
    • 5.15.4.2 Europe
    • 5.15.4.3 Asia Pacific
    • 5.15.4.4 Rest of the World
  • 5.15.5 IMPACT ON MANUFACTURING INDUSTRIES
• 5.16 UNMET NEEDS & WHITE SPACES

6 COMPOUNDING PHARMACY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ORAL DRUGS
  • 6.2.1 INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET
• 6.3 TOPICAL DRUGS
  • 6.3.1 RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH
• 6.4 PARENTERAL DRUGS
  • 6.4.1 RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH
• 6.5 OPTHALMIC DRUGS
  • 6.5.1 RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH
• 6.6 NASAL DRUGS
  • 6.6.1 ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH
• 6.7 RECTAL DRUGS
  • 6.7.1 PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES
• 6.8 OTHER PRODUCTS

7 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE

• 7.1 INTRODUCTION
• 7.2 PHARMACEUTICAL DOSAGE ALTERATION
  • 7.2.1 TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS
• 7.3 PHARMACEUTICAL INGREDIENTS ALTERATION
  • 7.3.1 INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS
• 7.4 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING
  • 7.4.1 PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION

8 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION

• 8.1 INTRODUCTION
• 8.2 PAIN MANAGEMENT
  • 8.2.1 NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET
• 8.3 HORMONE REPLACEMENT THERAPIES
  • 8.3.1 POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET
• 8.4 DERMAL DISORDERS
  • 8.4.1 CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION
• 8.5 NUTRITIONAL SUPPLEMENTS
  • 8.5.1 PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES
• 8.6 OTHER THERAPEUTIC APPLICATIONS

9 COMPOUNDING PHARMACY MARKET, BY STERILITY

• 9.1 INTRODUCTION
• 9.2 STERILE
  • 9.2.1 RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES
• 9.3 NON-STERILE
  • 9.3.1 503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES

10 COMPOUNDING PHARMACY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 ADULTS
  • 10.2.1 RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH
• 10.3 GERIATRIC PATIENTS
  • 10.3.1 AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH
• 10.4 PEDIATRIC PATIENTS
  • 10.4.1 CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH

11 COMPOUNDING PHARMACY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate North American compounding pharmacy market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Aging demographics, technological advancements, and supportive regulations to drive market
  • 11.3.3 UK
    • 11.3.3.1 Personalized treatments, chronic disease management, and regulatory support to support market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Focus on chronic disease management to fuel growth in French compounding pharmacy market
  • 11.3.5 ITALY
    • 11.3.5.1 Rising commercial drug development pipeline to spur market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Global regulatory advancements and rising R&D activities to drive market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing pharma R&D activities to support market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growing pharmacy & biologics manufacturing sectors and rising R&D sepnding to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023-2025
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Therapeutic application footprint
    • 12.5.5.5 Sterility footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startup/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 BAXTER
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 EMPOWER PHARMACY
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 B. BRAUN SE
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 FAGRON
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 QUVA PHARMA, INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Key strengths
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 SCA PHARMA
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
  • 13.1.7 NEPHRON PHARMACEUTICALS
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Expansions
  • 13.1.8 LEITERS HEALTH
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Expansions
  • 13.1.9 ICON GROUP
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
  • 13.1.10 ROSEWAY LABS
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Other developments
  • 13.1.11 ITH PHARMA
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 PENCOL COMPOUNDING PHARMACY
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 FORMUL8
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 AURORA COMPOUNDING PHARMACY
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 CUSTOM MED APOTHECARY
  • 13.2.2 INSTITUTIONAL PHARMACY SOLUTIONS
  • 13.2.3 FUSION APOTHECARY
  • 13.2.4 INNOVATION COMPOUNDING PHARMACY
  • 13.2.5 RX3 COMPOUNDING PHARMACY
  • 13.2.6 DOUGHERTY'S PHARMACY, INC.
  • 13.2.7 LORRAINE'S PHARMACY
  • 13.2.8 WELLS PHARMA
  • 13.2.9 OLYMPIA PHARMACY
  • 13.2.10 FRESH THERAPEUTICS
  • 13.2.11 MEDIOS AG

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS